Kahn Brothers Kahn Brothers Group
Kahn Brothers Group is a value investment firm founded in the tradition of Benjamin Graham and long associated with the Kahn family of investors. The firm is known for deep-value security analysis, patience, and a multi-decade orientation to intrinsic value. Its filings are followed by classic value investors seeking Graham-and-Dodd style managers still active in public markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$24.1M |
| 2 |
Patterson-UTI
PTEN
|
+$1.33M |
| 3 |
GSK
GSK
|
+$624K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
New York Times
NYT
|
+$16.5M |
| 2 |
HOLX
Hologic
HOLX
|
+$9.46M |
| 3 |
Merck
MRK
|
+$3.71M |
| 4 |
STL
Sterling Bancorp
STL
|
+$2.8M |
| 5 |
BP
BP
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 33.44% |
| 2 | Healthcare | 29.35% |
| 3 | Energy | 13.44% |
| 4 | Technology | 9.78% |
| 5 | Consumer Staples | 4.9% |
Similar funds
Kahn Brothers's Q1 2019 Portfolio in Review
As of Q1 2019, Kahn Brothers held 32 positions worth $640M, up 15% from $555M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Trading was light in Q1 2019: portfolio turnover was 3.1%. Kahn Brothers opened 1 new position and made no exits, leaving the 32-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 33% of assets, down from 34% a quarter earlier, followed by Healthcare and Energy.
- Kahn Brothers added most to Bristol-Myers Squibb in Q1 2019, an estimated $24.1M increase.
- Kahn Brothers's biggest Q1 2019 reduction was New York Times, cutting an estimated $16.5M.
- Kahn Brothers's ten largest holdings make up 76% of its $640M portfolio in Q1 2019.
- Kahn Brothers opened 1 new position and closed 0 in Q1 2019.
- Kahn Brothers's portfolio value rose 15% quarter-over-quarter to $640M.
Based on Kahn Brothers Group's 13F filing for Q1 2019, filed 6 May 2019.